Prostate Cancer Clinical Trials in Salt Lake City, Utah

8 studies are recruiting for prostate cancer in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

   The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Salt Lake City, Utah

   Locations

   346 in total

   Run by

   AstraZeneca

   See if you can join NCT06952803 on ClinicalTrials.gov

2. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

3. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

4. A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

   ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Salt Lake City, Utah

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07336446 on ClinicalTrials.gov

5. Pembro With Radiation With or Without Olaparib

   This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   2 in total

   Run by

   Zin W Myint

   See if you can join NCT05568550 on ClinicalTrials.gov

6. Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer

   Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), and via direct side effects of androgen deprivation therapy (…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT07093177 on ClinicalTrials.gov

7. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Care - Mountain Region, Salt Lake City, Utah

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

8. Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer

   People with prostate cancer may have a decreased quality of life due to the cancer itself and due to a lifesaving cancer treatment. Physical therapy, including regular exercise, helps patients with cancer to reduce disease symptoms and improve their quality of life. However, cancer rehabilitation p…

   Stage

   Not phased

   Ages

   21 and older

   Site

   University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT07032584 on ClinicalTrials.gov